The AIDS Clinical Trials Unit (CTU) and Virology Support Laboratory (VSL) at Stanford University have been affiliated with the AIDS Clinical Trials Group since its inception in 1987 and has enrolled well over 1000 patients into ACTG trials. During this time Stanford investigators have served in man>different leadership capacities within the ACTG and have made significant contributions to the treatment of HIV infection through these efforts. Our CTU investigators and staff are now poised to build on this record cf scientific contribution within the context of the restructured clinical trials network. The Stanford CTU focuses primarily on the development, evaluation and optimization of combination antiretroviral drug therapy (ART) for the treatment and long-term management of HIV-1 infection including the use of novel agents and technologies for monitoring treatment efficacy. Our group has a particular interest in the basic mechanisms and clinical implications of drug resistance in HIV-1. The Stanford VSL is focused on drug resistance and subtype diversity of non-clade B isolates and has been designated as the drug resistance reference testing laboratory in the International-ACTG and ACTG network application. In addition, the Stanford group has developed a database which links HIV treatment histories and treatment outcomes to genotypic and phenotypic drug resistance patterns. Advanced informatics databases that manage """"""""high-dimensional"""""""" data- like drug resistance data and pharmacogenomics data will likely become increasingly important resources for our understanding of the determinates of health and disease, response to treatment and risk of drug toxicities as we move forward in the next 5-10 years. The Stanford CTU comprises three Clinical Research sites with ethnically and socially diverse patient populations: (i) Stanford University's Positive Care Clinic in Palo Alto, (ii) The PACE Clinic at Santa Clara Valley Medical Center in central San Jose, and (iii) The Edison Clinic, run by the San Mateo County AIDS Program at San Mateo Medical Center. Through this constellation of sites we have always exceeded our community-based targets for under represented ethnic groups and women in ACTG trial enrollment. Although this working arrangement has been successful for over 10 years, further consolidations and streamlining described here will ensure that the proposed CTU and CRSs will be even more efficient.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-AR-A (M1))
Program Officer
Sachau, Bill R
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Stanford University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Bednasz, Cindy J; Venuto, Charles S; Ma, Qing et al. (2017) Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants. Ther Drug Monit 39:596-603
Verma, Anurag; Bradford, Yuki; Verma, Shefali S et al. (2017) Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 27:101-111
Riddler, Sharon A; Aga, Evgenia; Bosch, Ronald J et al. (2016) Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy. J Infect Dis 213:556-60
Landovitz, Raphael J; Tran, Thuy Tien T; Cohn, Susan E et al. (2016) HIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-Naïve Men and Women in the United States. AIDS Behav 20:2983-2995
Jacobson, Jeffrey M; Zheng, Lu; Wilson, Cara C et al. (2016) The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection. J Acquir Immune Defic Syndr 71:163-71
Verma, Shefali S; Frase, Alex T; Verma, Anurag et al. (2016) PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG). Pac Symp Biocomput 21:57-68
Tenorio, Allan R; Chan, Ellen S; Bosch, Ronald J et al. (2015) Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286. J Infect Dis 211:780-90
Cillo, Anthony R; Hilldorfer, Benedict B; Lalama, Christina M et al. (2015) Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery. AIDS 29:2121-9
Lehmann, David S; Ribaudo, Heather J; Daar, Eric S et al. (2015) Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols. Pharmacogenet Genomics 25:51-9
Moore, Carrie B; Verma, Anurag; Pendergrass, Sarah et al. (2015) Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols. Open Forum Infect Dis 2:ofu113

Showing the most recent 10 out of 81 publications